Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Tenaya Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401 Anticipated in Second Half 2023 Second Quarter Cash and Investments of $152 Million; Runway to Fund Operations into First Half 2025 SOUTH SAN FRANCISCO, Calif., August 9, 2023 -- Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023. “We are looking ahead..."
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Certificate of Amendment to THE Amended and Restated Certificate of Incorporation of TENAYA THERAPEUTICS, Inc.",
"TENAYA THERAPEUTICS, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION 1. Introduction. The purpose of this Tenaya Therapeutics, Inc. Executive Change in Control and Severance Plan is to provide assurances of specified benefits to certain employees of the Company whose employment could be being involuntarily terminated other than for death, Disability, or Cause or voluntarily terminated for Good Reason under the circumstances described in the Plan. This Plan is an “employee welfare benefit plan,” as defined in Section 3 of ERISA. This document is both the written instrument under which the Plan is maintained and the required summary plan description for the Plan. 2. Important Terms. The following words and phrases, when the initial letter of the..."
05/10/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory Board with Deep Expertise in Gene Therapy Manufacturing SOUTH SAN FRANCISCO, Calif., May 10, 2023 -- Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the first quarter ended March 31, 2023. “Tenaya is making ..."
03/08/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update TN-201 IND Cleared in January; Plan to Begin Phase 1b Dosing in MYBPC3-associated HCM Patients in Third Quarter 2023 Dosing Commenced in Multiple-Ascending Dose Stage of First-In-Human Clinical Trial of TN-301; Data Anticipated in Second Half 2023 2022 Year End Cash and Investments of $204 Million; Runway to Fund Operations into First Half 2025 South San Francisco, Calif. – March 8, 2023 – Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2022 and p..."
12/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors SOUTH SAN FRANCISCO, Calif., – December 7, 2022 – Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. “We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercial launch of innovative products will be directly relevant..."
11/17/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, among Tenaya Therapeutics, Inc. and the Representatives",
"Form of Pre-Funded Warrant",
"Opinion of Wilson Sonsini Goodrich & Rosati, P.C",
"Tenaya Therapeutics Announces Pricing of Public Offering"
08/10/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, between Tenaya Therapeutics, Inc. and SVB Securities LLC"
08/10/2022 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and Capsid Engineering Efforts South San Francisco, Calif. – Aug. 10, 2022—Tenaya Therapeutics, Inc. , a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022. “Tenaya continues to make strides forward in our transition to becoming a fully integrated clinical-stage company and continues to invest ..."
06/10/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2022 8-K Quarterly results
03/23/2022 8-K Quarterly results
12/22/2021 8-K Quarterly results
11/22/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors SOUTH SAN FRANCISCO, Calif.——Nov. 22, 2021— Tenaya Therapeutics, Inc. , a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced changes to its Board of Directors including the addition of June Lee, M.D., and the transition of JJ Kang, Ph.D., who will be stepping down after five years of service. “We are thrilled to welcome Dr. Lee to our Board at an important inflection point as we continue our transition towards becoming a clinical-stage company,” said Faraz Ali, CEO of Tenaya. “Dr. Lee brings a wealth of highly relevant strategic and operational development experience to Tenaya and is well-positioned t..."
11/10/2021 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates - Initiated global natural history study for pediatric patients with MYBPC3 mutation to support clinical development of TN-201 gene therapy -"
09/08/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy